Aporte a la rutina de la trinchera asistencial donde los conocimientos se funden con las demandas de los pacientes, sus necesidades y las esperanzas de permanecer en la gracia de la SALUD.
IPIC 5th Edition
IPIC 5th Edition video on demand (VOD)
is now available
Wish you had been able to attend IPIC 5th Edition? Or perhaps you did attend but missed a lecture? You can now access the recorded sessions!
IPIC 5th Edition in-person participants have complimentary access to various recordings of the Scientific Programme sessions and discussions, please log in to the congress web app. Details regarding unique sign-in codes were outlined within the logistical information email previously sent to all participants. Online recordings as well as access to the congress app will be available until Thursday 30 July 2022.
We invite all those who were unfortunately unable to attend in-person to register at a discounted rate for VOD access here. VOD registered participants can request an event participation certificate through the congress web app which will be sent via email until Thursday 30 July 2022. Please kindly note that CME accreditation is not possible for VOD registered participants. For further assistance please contact the congress secretariat via ipic5edition@aimgroup.eu
Once again, a big thank you to our IPIC 5th Edition participants and all those who were involved in this important event. See you in Rotterdam for IPIC2023!
Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19 | FDA
The FDA first issued an emergency use authorization (EUA) for Olumiant in combination with remdesivir to treat COVID-19 in hospitalized adults and pediatric patients on November 19, 2020. On July 28, 2021, the FDA revised the EUA to authorize Olumiant as a standalone treatment. Olumiant remains under EUA status for hospitalized pediatric patients 2 to less than 18 years of age requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO. The FDA has revised the Letter of Authorization and associated fact sheets to remove the population covered under the approved indication.
label
Today, the FDA approved a new indication for Olumiant (baricitinib) for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Olumiant is the first immunomodulatory treatment for COVID-19 to receive FDA approval.
ver historia personal en: www.cerasale.com.ar [dado de baja por la Cancillería Argentina por temas políticos, propio de la censura que rige en nuestro medio]//
www.revistamedicos.com.ar //
www.quorumtuc.com.ar //
www.sectorsalud.com.ar //
www.maimonides.edu //
weblog.maimonides.edu/farmacia/archives/UM_Informe_Autoevaluacion_FyB.pdf - //
weblog.maimonides.edu/farmacia/archives/0216_Admin_FarmEcon.pdf - //
www.documentalistas.org.ar //
www.cpcesfe2.org.ar //
www.nogracias.eu //
www.estenssorome.com.ar //
www.cuautitlan.unam.mx/descargas/licenciaturas/bqd/plandestudio_bqd_ //
www.latamjpharm.org/trabajos/25/2/LAJOP_25_2_6_1_M4M6Z9746D.pdf //
www.nogracias.eu/v_juventud/informacion/informacionver.asp?cod= //
www.colfarse.com.ar //
www.proz.com/kudoz/english_to_spanish/art_literary/523942-key_factors.html - 65k - // www.llave.connmed.com.ar/portalnoticias_vernoticia.php?codigonoticia=17715 // www.frusculleda.com.ar/homepage/espanol/activities_teaching.htm // http://www.on24.com.ar/nota.aspx?idNot=36331 ||